|

Insulin aspart Clinical Trials

6 actively recruiting trials across 2 locations

▼ -1 trial since July 2026

Pipeline

Early 1: 2Phase 2: 1Phase 3: 1

Top Sponsors

  • Anna Stanhewicz, PhD2
  • Novo Nordisk A/S1
  • Gan and Lee Pharmaceuticals, USA1
  • Defymed1
  • Beijing Hospital1

Indications

  • Diabetes6
  • Gestational Diabetes2
  • Type 2 Diabetic Patients1
  • T2DM (Type 2 Diabetes Mellitus)1
  • Vascular Endothelial Function1

Other3 trials

A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD
Phase 2
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
N/A
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes
N/A

Iowa City, Iowa2 trials

Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes

University of Iowa

Early 1
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

University of Iowa

Early 1

Cullman, Alabama1 trial

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Cullman Clinical Trials

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.